Changes in HIV-Related Cervical Cancer Over a Decade in Côte d'Ivoire

• Published in: JCO global oncology Vol. 7; no. 7; pp. 782 - 789
• Main Authors: Jaquet, Antoine, Boni, Simon, Tchounga, Boris, Comoe, Kouassi, Tanon, Aristophane, Horo, Apollinaire, Diomandé, Isidore, Didi-Kouko Coulibaly, Judith, Ekouevi, Didier K, Adoubi, Innocent
• Format: Journal Article
• Language: English
• Published: United States American Society of Clinical Oncology 01.05.2021; Wolters Kluwer Health
• Subjects: Cancer; CD4 Lymphocyte Count; Cote d'Ivoire - epidemiology; Cross-Sectional Studies; Female; Gynecology and obstetrics; HIV Infections - drug therapy; HIV Infections - epidemiology; Human health and pathology; Humans; Infectious diseases; Life Sciences; ORIGINAL REPORTS; Pregnancy; Santé publique et épidémiologie; Uterine Cervical Neoplasms - diagnosis; Uterine Cervical Neoplasms - epidemiology; Cote d'Ivoire
• ISSN: 2687-8941; 2687-8941
• DOI: 10.1200/GO.21.00006

Major improvements have occurred in access to invasive cervical cancer (ICC) screening in HIV-infected women over the past decade in sub-Saharan Africa. However, there is limited information on changes in the burden of HIV-related ICC at a population level. Our objective was to compare HIV-related ICC over a decade and document factors associated with HIV infection in women with ICC in Côte d'Ivoire. A repeated cross-sectional study was conducted in referral hospitals of Abidjan, Côte d'Ivoire, through the 2009-2011 and 2018-2020 periods. Women diagnosed with ICC were systematically tested for HIV. Demographics, ICC risk factors, cancer stage (International Federation of Gynecology and Obstetrics), and HIV characteristics were collected through questionnaires. Characteristics of HIV-related ICC were compared between the periods, and factors associated with HIV in women diagnosed with ICC in 2018-2020 were documented through a multivariable logistic model. During the 2009-2011 and 2018-2020 periods, 147 and 297 women with ICC were diagnosed with estimated HIV prevalence of 24.5% and 21.9% ( = .53), respectively. In HIV-infected women, access to antiretroviral treatment increased from 2.8% to 73.8% ( < 10 ) and median CD4 cell count from 285 (IQR, 250-441) to 492 (IQR, 377-833) cells/mm ( = .03). In women diagnosed with ICC during the 2018-2020 period, HIV infection was associated with a less advanced clinical stage (International Federation of Gynecology and Obstetrics I or II stage) (adjusted OR, 2.2 [95% CI, 1.1 to 4.4]) and with ICC diagnosis through a systematic screening (adjusted OR, 10.5 [95% CI, 2.5 to 45.5]). Despite a persistently high proportion of HIV-related ICC over time in Côte d'Ivoire, HIV was associated with less advanced clinical stage at ICC diagnosis. Recent improvements in ICC screening services across HIV clinics might explain this association and support their implementation across non-HIV health facilities.